Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease. The article documents the prior $600M Dren Bio acquisition of DR-0201 deep B-cell…
Sanofi and Dren Bio are expanding their B-cell depletion collaboration with a new $1.8 billion biobucks deal focused on a next-generation successor to…
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+. The article frames the Kali deal as the latest in a string of Sanofi immunology pacts that…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Sanofi expanded collaboration with Dren Bio for discovery and development of next-generation B-cell depletion therapy. $100M upfront and up to $1.7B in development/regulatory/commercial milestones. Dren has option for 40% co-funding/50% US profit share arrangement. Builds on March 2025 DR-0201 acquisition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Dren Bio, Inc. (this deal) | 2025 | $1.8B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2025 deals · Sanofi SA deals · Immunology deals